Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by ImmunoGen Inc. ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH December 10, 2023 From ImmunoGen Inc. Via Business Wire Tickers IMGN ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results November 02, 2023 From ImmunoGen Inc. Via Business Wire Tickers IMGN ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2023 Operating Results October 19, 2023 From ImmunoGen Inc. Via Business Wire Tickers IMGN ELAHERE® Shows Overall and Progression-Free Survival Benefit Regardless of Prior PARPi Exposure or Prior Lines of Therapy in FRα-Positive Platinum-Resistant Ovarian Cancer September 28, 2023 From ImmunoGen Inc. Via Business Wire Tickers IMGN ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2023 Operating Results July 17, 2023 From ImmunoGen Inc. Via Business Wire Tickers IMGN ImmunoGen Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at EHA 2023 Congress June 09, 2023 From ImmunoGen Inc. Via Business Wire Tickers IMGN ELAHERE® Demonstrates 35% Reduction in the Risk of Disease Progression or Death Versus Chemotherapy in FRα-Positive Platinum-Resistant Ovarian Cancer June 04, 2023 From ImmunoGen Inc. Via Business Wire Tickers IMGN ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock May 04, 2023 From ImmunoGen Inc. Via Business Wire Tickers IMGN ELAHERE® Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRα-Positive Platinum-Resistant Ovarian Cancer May 03, 2023 From ImmunoGen Inc. Via Business Wire Tickers IMGN ImmunoGen Announces Conference Call to Discuss Its First Quarter 2023 Operating Results April 13, 2023 From ImmunoGen Inc. Via Business Wire Tickers IMGN ImmunoGen Announces Conference Call to Discuss Its 2022 Operating Results February 15, 2023 From ImmunoGen Inc. Via Business Wire Tickers IMGN ImmunoGen Announces FDA Accelerated Approval of ELAHERE™ (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer November 14, 2022 From ImmunoGen Inc. Via Business Wire Tickers IMGN ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2022 Operating Results October 20, 2022 From ImmunoGen Inc. Via Business Wire Tickers IMGN ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2022 Operating Results July 14, 2022 From ImmunoGen Inc. Via Business Wire Tickers IMGN ImmunoGen Announces Research Collaboration with Oxford BioTherapeutics to Develop Novel Antibody-Drug Conjugates June 13, 2022 From ImmunoGen Inc. Via Business Wire Tickers IMGN ImmunoGen Announces Conference Call to Discuss Its First Quarter 2022 Operating Results April 21, 2022 From ImmunoGen Inc. Via Business Wire Tickers IMGN ImmunoGen Reports Recent Progress and 2021 Financial Results February 25, 2022 From ImmunoGen Inc. Via Business Wire Tickers IMGN ImmunoGen Announces a Global, Multi-Target License Agreement of its Novel Camptothecin ADC Platform to Lilly for Up to $1.7 Billion February 15, 2022 From ImmunoGen Inc. Via Business Wire Tickers IMGN ImmunoGen Announces Conference Call to Discuss Its 2021 Operating Results February 10, 2022 From ImmunoGen Inc. Via Business Wire Tickers IMGN ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 01, 2022 From ImmunoGen Inc. Via Business Wire Tickers IMGN ImmunoGen Appoints Mimi Huizinga, MD, as Senior Vice President and Head of Medical Affairs January 31, 2022 From ImmunoGen Inc. Via Business Wire Tickers IMGN ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 03, 2022 From ImmunoGen Inc. Via Business Wire Tickers IMGN ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock December 02, 2021 From ImmunoGen Inc. Via Business Wire Tickers IMGN ImmunoGen Announces Proposed Public Offering of Common Stock November 30, 2021 From ImmunoGen Inc. Via Business Wire Tickers IMGN ImmunoGen Announces Positive Top-Line Results from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer November 30, 2021 From ImmunoGen Inc. Via Business Wire Tickers IMGN ImmunoGen Appoints Tracey L. McCain, Esq. to Its Board of Directors November 17, 2021 From ImmunoGen Inc. Via Business Wire Tickers IMGN ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 16, 2021 From ImmunoGen Inc. Via Business Wire Tickers IMGN ImmunoGen Appoints Kristen Harrington-Smith as Senior Vice President and Chief Commercial Officer November 16, 2021 From ImmunoGen Inc. Via Business Wire Tickers IMGN ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 01, 2021 From ImmunoGen Inc. Via Business Wire Tickers IMGN ImmunoGen Reports Recent Progress and Third Quarter 2021 Financial Results October 29, 2021 From ImmunoGen Inc. Via Business Wire Tickers IMGN Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.